All of the shares are being sold by NeuroPace. The aggregate gross proceeds from the offering are expected to be $65 million, before deducting the underwriting discounts and commissions and offering expenses. 

The offering is expected to close on February 18, 2025, subject to customary closing conditions.

NeuroPace expects to use approximately $49.5 million of the net proceeds from the offering to repurchase 5.27 million shares held by NeuroPace's significant stockholder, KCK Ltd., at $9.40 per share, which is the price per share at which the underwriters will purchase shares of NeuroPace's common stock from the company in the public offering.